Literature DB >> 16598528

Implementation of evidence-based therapy in patients with systolic heart failure from 1998-2000.

R Reibis1, C Dovifat, R Dissmann, B Ehrlich, S Schulz, K Stolze, K Wegscheider, H Völler.   

Abstract

BACKGROUND: In recent years, the incidence of systolic heart failure has increased. Besides a complete revascularization, guideline-based medication represents the most effective therapeutic approach. AIM: Analysis of adherence of guideline-recommended and actual medication during inpatient cardiac rehabilitation as well as under subsequent outpatient conditions.
METHODS: From 01/1998 to 12/ 2000, 1346 consecutive patients (64 +/- 10 years, 73% male, LVEF 36.3 +/- 8%, 88% ischemic, 6.7% valvular cardiomyopathy, 5.3% other causes, 11.8% atrial fibrillation) were included in a singlecenter prospective register. Medication was recorded at discharge and after the follow-up period of 731 +/- 215 days. Trends in prescription rates were analyzed based on nonparametric correlations (Spearman's-Rho). Changes in medication from in- to outpatient settings were analyzed using exact McNemar test.
RESULTS: At discharge 75.3% (67.9%/68.9%/ 86.6% in 1998/1999/2000, p <0.001) of the patients were treated as recommended. This rate dropped to 68.3% at followup (p <0.0001). Mortality within the follow-up period was low (12.6%).
CONCLUSION: It could be shown that from 1998 to 2000 inpatient guideline conformity was implementable adequately. Outpatient conformity was significantly lower. Although a high proportion of correctly prescribed CHF medication could be demonstrated, a further effort to improve guideline adherence in the management of heart failure patients is desirable.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16598528     DOI: 10.1007/s00392-006-0348-0

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  30 in total

1.  Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology.

Authors:  Willem J Remme; Karl Swedberg
Journal:  Eur J Heart Fail       Date:  2002-01       Impact factor: 15.534

Review 2.  [Guidelines for therapy of chronic heart failure. German Society of Cardiology-Heart and Cardiovascular Research].

Authors:  U C Hoppe; E Erdmann
Journal:  Z Kardiol       Date:  1998-08

3.  ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure).

Authors:  S A Hunt; D W Baker; M H Chin; M P Cinquegrani; A M Feldman; G S Francis; T G Ganiats; S Goldstein; G Gregoratos; M L Jessup; R J Noble; M Packer; M A Silver; L W Stevenson; R J Gibbons; E M Antman; J S Alpert; D P Faxon; V Fuster; A K Jacobs; L F Hiratzka; R O Russell; S C Smith
Journal:  J Am Coll Cardiol       Date:  2001-12       Impact factor: 24.094

4.  More 'malignant' than cancer? Five-year survival following a first admission for heart failure.

Authors:  S Stewart; K MacIntyre; D J Hole; S Capewell; J J McMurray
Journal:  Eur J Heart Fail       Date:  2001-06       Impact factor: 15.534

5.  Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey.

Authors:  Michel Komajda; Pablo Lapuerta; Nancy Hermans; José Ramon Gonzalez-Juanatey; Dirk J van Veldhuisen; Erland Erdmann; Luigi Tavazzi; Philip Poole-Wilson; Claude Le Pen
Journal:  Eur Heart J       Date:  2005-04-12       Impact factor: 29.983

6.  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

Authors: 
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

7.  Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study.

Authors:  Sumit R Majumdar; Finlay A McAlister; Marilyn Cree; Wei-Ching Chang; Milton Packer; Paul W Armstrong
Journal:  Clin Ther       Date:  2004-05       Impact factor: 3.393

8.  Prescription patterns of diuretics in chronic heart failure: a contemporary background as a clue to their role in treatment.

Authors:  Pompilio Faggiano; Cristina Opasich; Luigi Tavazzi; Felice Achilli; Anna Gentile; Luciano De Biase; Renata De Maria; Roberto Pozzi; Luigi Tarantini; Lucio Gonzini; Aldo P Maggioni
Journal:  J Card Fail       Date:  2003-06       Impact factor: 5.712

9.  Management of chronic heart failure due to systolic left ventricular dysfunction by cardiologist and non-cardiologist physicians.

Authors:  Sinéad P McKee; Stephen J Leslie; John P LeMaitre; David J Webb; Martin A Denvir
Journal:  Eur J Heart Fail       Date:  2003-08       Impact factor: 15.534

10.  Patterns of beta-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic.

Authors:  Ritesh Gupta; W H Wilson Tang; James B Young
Journal:  Am Heart J       Date:  2004-01       Impact factor: 4.749

View more
  9 in total

1.  Beta blockers and glucose metabolism in chronic heart failure: friend or foe?

Authors:  W Doehner; S D Anker
Journal:  Clin Res Cardiol       Date:  2008-01       Impact factor: 5.460

2.  Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib.

Authors:  E Chorianopoulos; D Jäger; H A Katus; N Frey
Journal:  Clin Res Cardiol       Date:  2007-08-21       Impact factor: 5.460

3.  Exercise capacity is the most powerful predictor of 2-year mortality in patients with left ventricular systolic dysfunction.

Authors:  Rona K Reibis; Andras Treszl; Karl Wegscheider; Bettina Ehrlich; Rüdiger Dissmann; Heinz Völler
Journal:  Herz       Date:  2010-04-08       Impact factor: 1.443

4.  Primary ICD-therapy in patients with advanced heart failure: selection strategies and future trials.

Authors:  Lutz Frankenstein; Christian Zugck; Manfred Nelles; Dieter Schellberg; Andrew Remppis; Hugo Katus
Journal:  Clin Res Cardiol       Date:  2008-03-17       Impact factor: 5.460

Review 5.  The case for statin therapy in chronic heart failure.

Authors:  Pim van der Harst; Michael Böhm; Wiek H van Gilst; Dirk J van Veldhuisen
Journal:  Clin Res Cardiol       Date:  2007-12-01       Impact factor: 5.460

6.  Atrial tachycardias following circumferential pulmonary vein ablation: observations during catheter ablation.

Authors:  Marc Horlitz; Philipp Schley; Dong-In Shin; Beatrice Tonnellier; Hartmut Gülker
Journal:  Clin Res Cardiol       Date:  2007-11-28       Impact factor: 5.460

7.  Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy.

Authors:  F Peters-Klimm; T Müller-Tasch; D Schellberg; A Remppis; A Barth; N Holzapfel; J Jünger; W Herzog; J Szecsenyi
Journal:  Clin Res Cardiol       Date:  2007-11-28       Impact factor: 5.460

Review 8.  [Rehabilitation 2008: when to use outpatient and inpatient rehabilitation?].

Authors:  Gregor Sauer
Journal:  Herz       Date:  2008-09       Impact factor: 1.443

9.  Long-term prognosis after cardioversion of the first episode of symptomatic atrial fibrillation: a condition believed to be benign revised.

Authors:  Torsten Becker; Thomas Kleemann; Margit Strauss; Klaus Doenges; Steffen Schneider; Jochen Senges; Karlheinz Seidl
Journal:  Clin Res Cardiol       Date:  2007-10-19       Impact factor: 5.460

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.